Although there is no clear evidence for superiority of first-line platinum agents over non-platinum agents in pancreatic cancer for BRCA1/2 or PALB2 mutant carriers, the latest National Comprehensive Cancer Network guidelines recommend FOLFIRINOX or modified FOLFIRINOX or gemcitabine plus cisplatin as first-line chemotherapy for known BRCA1/2 or PALB2 mutated cases [133]. This evidence concerns the gene BRCA1 and pancreatic neoplasm.